Compare · CHWY vs LOGC
CHWY vs LOGC
Side-by-side comparison of Chewy Inc. (CHWY) and ContextLogic Inc. (LOGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHWY and LOGC operate in Catalog/Specialty Distribution (Consumer Discretionary), so they compete in similar markets.
- CHWY is the larger of the two at $8.37B, about 171.6x LOGC ($48.8M).
- Over the past year, CHWY is down 44.0% and LOGC is up 0.0% - LOGC leads by 44.0 points.
- CHWY has more recent analyst coverage (25 ratings vs 5 for LOGC).
- Company
- Chewy Inc.
- ContextLogic Inc.
- Price
- $21.34+2.38%
- $7.05+1.00%
- Market cap
- $8.37B
- $48.8M
- 1M return
- +1.94%
- +0.00%
- 1Y return
- -44.01%
- +0.00%
- Industry
- Catalog/Specialty Distribution
- Catalog/Specialty Distribution
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 0
- 0
- Recent ratings
- 25
- 5
Chewy Inc.
Chewy, Inc., together with its subsidiaries, engages in the pure play e-commerce business in the United States. The company provides pet food and treats, pet supplies and pet medications, and other pet-health products, as well as pet services for dogs, cats, fish, birds, small pets, horses, and reptiles through its chewy.com retail Website, as well as its mobile applications. It offers approximately 70,000 products from 2,500 partner brands. The company was founded in 2010 and is headquartered in Dania Beach, Florida. Chewy, Inc. is a subsidiary of PetSmart, Inc.
ContextLogic Inc.
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.
Latest CHWY
- SEC Form S-3ASR filed by Chewy Inc.
- Chewy downgraded by Analyst with a new price target
- Chewy downgraded by Evercore ISI with a new price target
- SEC Form 10-Q filed by Chewy Inc.
- Chewy Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Chewy Announces Second Quarter 2026 Financial Results
- General Counsel & Secretary Hu Da-Wai covered exercise/tax liability with 445 shares, decreasing direct ownership by 10% to 4,203 units (SEC Form 4) (for tax liability)
- Chief Accounting Officer Billings William G. covered exercise/tax liability with 625 shares, decreasing direct ownership by 1% to 57,055 units (SEC Form 4) (for withholding tax)
- Chief Financial Officer Deppe Christopher S. covered exercise/tax liability with 1,541 shares, decreasing direct ownership by 14% to 9,576 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Singh Sumit covered exercise/tax liability with 8,840 shares, decreasing direct ownership by 0.84% to 898,291 units (SEC Form 4) to cover taxes
Latest LOGC
- ContextLogic Holdings Inc. Publishes Q&A Following Second Quarter 2026 Results
- SEC Form 10-Q filed by ContextLogic Inc.
- ContextLogic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial Results
- ContextLogic Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- ContextLogic to Acquire gChem for $850 Million
- Amendment: ContextLogic Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- ContextLogic Appoints Seth Siegel as Senior Advisor
- ContextLogic Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- CFO & COO Stewart Scott Matthew bought $97,600 worth of shares (10,000 units at $9.76), increasing direct ownership by 20% to 60,000 units (SEC Form 4)